Company intelligence / Profile preview

LeukePharma

Halle (Saale), Saxony-Anhalt, Germany

Ownership: Private
Development stage: Other

Overview

LeukePharma is a German biotechnology company specializing in the development of targeted therapies for pediatric and adult Acute Myeloid Leukemia (AML). The company's research focuses on the molecular drivers of leukemia, particularly the GATA1 mutation found in Down Syndrome-associated myeloid leukemia. By leveraging deep insights into hematopoiesis and leukemogenesis, LeukePharma aims to develop precision medicines that improve survival rates and reduce toxicity for patients with high-risk leukemia. Their lead programs involve small molecule inhibitors designed to disrupt oncogenic signaling pathways.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Martin Luther University Halle-WittenbergHannover Medical School

Beyond the preview

Go deeper on LeukePharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LeukePharma.

Explore the full profile